Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Greenland Mines Ltd. Common Stock (NASDAQ:GRML) to a sell rating in a research note released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Greenland Mines Ltd. Common Stock in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Greenland Mines Ltd. Common Stock Stock Performance

Shares of GRML opened at $0.52 on Friday. Greenland Mines Ltd. Common Stock has a twelve month low of $0.12 and a twelve month high of $3.91. The firm’s 50 day moving average price is $0.50 and its two-hundred day moving average price is $0.43. The firm has a market cap of $62.51 million, a P/E ratio of -1.61 and a beta of 7.63.

Hedge Funds Weigh In On Greenland Mines Ltd. Common Stock

A number of institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Greenland Mines Ltd. Common Stock during the second quarter worth $26,000. XTX Topco Ltd increased its holdings in Greenland Mines Ltd. Common Stock by 101.2% during the fourth quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after buying an additional 80,768 shares during the last quarter. Geode Capital Management LLC increased its holdings in Greenland Mines Ltd. Common Stock by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after buying an additional 167,905 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Greenland Mines Ltd. Common Stock during the fourth quarter worth $126,000. Finally, Brummer Multi Strategy AB acquired a new position in Greenland Mines Ltd. Common Stock during the fourth quarter worth $175,000. 20.07% of the stock is currently owned by institutional investors and hedge funds.

Greenland Mines Ltd. Common Stock Company Profile

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.